Skip to main content
. Author manuscript; available in PMC: 2017 Sep 1.
Published in final edited form as: Lung Cancer. 2016 Jun 14;99:17–22. doi: 10.1016/j.lungcan.2016.06.006

Figure 3. ALK kinase domain mutants and EML4-ALK+ALK-S1206F.

Figure 3

A. Crizotinib 50% inhibitory concentration (IC50) fold changes induced by different ALK kinase mutants in the background of EML4-ALK-E13;A20, as reported by Friboulet et al (reference 10), tabulated with possible clinical response to achievable concentrations of crizotinib 250mg twice daily. B. Computed tomography (CT) to exemplify response to crizotinib in the patient whose lung adenocarcinoma harbored de novo EML4-ALK-E5;A20+ALK-S1206F. Shown are pre-crizotinib (baseline), month 1 and month 2 of crizotinib 250mg twice daily representative images. The white arrows highlight sites of tumor burden in the thorax and liver.